Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 166-181 http://medscipublisher.com/index.php/cge 179 Feng Y., Spezia M., Huang S., Yuan C., Zeng Z., Zhang L., Ji X., Liu W., Huang B., Luo W., Liu B., Lei Y., Du S., Vuppalapati A., Luu H., Haydon R., He T., and Ren G., 2018, Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis, Genes and Diseases, 5(2): 77-106. https://doi.org/10.1016/j.gendis.2018.05.001 Forbes C., Fayter D., de Kock S., and Quek R.G., 2019, A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer, Cancer Management and Research, 2321-2337. https://doi.org/10.2147/CMAR.S189627 Ford D., Easton D., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B., Gayther S., Birch J., Lindblom A., Stoppa-Lyonnet D., Bignon Y., Borg Å., Hamann U., Haites N., Scott R., Maugard C., Vasen H., Seitz S., Cannon-Albright L., Schofield A., and Zelada-Hedman M., 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families, The American Journal of Human Genetics, 62(3): 676-689. https://doi.org/10.1086/301749 Gracia-Aznárez F., Fernández V., Pita G., Peterlongo P., Domínguez O., Hoya M., Durán M., Osorio A., Moreno L., González-Neira A., Rosa-Rosa J., Sinilnikova O., Mazoyer S., Hopper J., Lázaro C., Southey M., Odefrey F., Manoukian S., Catucci I., Caldés T., Lynch H., Hilbers F., Asperen C., Vasen H., Goldgar D., Radice P., Devilee P., and Benítez J., 2013, Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles, PloS one, 8(2): e55681. https://doi.org/10.1371/journal.pone.0055681 Gray J.S., Wani S.A., and Campbell M.J., 2022, Epigenomic alterations in cancer: mechanisms and therapeutic potential. Clinical Science, 136(7): 473-492. https://doi.org/10.1042/CS20210449 Guerra Y., Alfaro A., Vzquez C., Bedoya A., Arteaga J., Zamora J., Sánchez-Román S., Maza D., Villarreal-Garza C., Reynoso N., Mohar A., and Mercado J., 2023, A randomized controlled trial evaluating pretest cancer genetics educational video or in-person genetic counseling, Journal of Clinical Oncology, 41(16): 10597. https://doi.org/10.1200/JCO.2023.41.16_suppl.10597 Guo X., Lin W., Bao J., Cai Q., Pan X., Bai M., Yuan Y., Shi J., Sun Y., Han M., Wang J., Liu Q., Wen W., Li B., Long J., Chen J., and Zheng W., 2018, A comprehensive cis-eQTL analysis revealed target genes in breast cancer susceptibility loci identified in genome-wide association studies, The American Journal of Human Genetics, 102(5): 890-903. https://doi.org/10.1016/j.ajhg.2018.03.016 Hammer M.J., 2019, February, Beyond the helix: Ethical, legal, and social implications in genomics, Seminars in Oncology Nursing, 35(1): 93-106. https://doi.org/10.1016/j.soncn.2018.12.007 Hampel H., Bennett R., Buchanan A., Pearlman R., and Wiesner G., 2015, A practice guideline from the american college of medical genetics and genomics and the national society of genetic counselors: referral indications for cancer predisposition assessment, Genetics in Medicine, 17(1): 70-87. https://doi.org/10.1038/gim.2014.147 Hazra A., Bose P., Sunita P., and Pattanayak S., 2021, Molecular epigenetic dynamics in breast carcinogenesis, Archives of Pharmacal Research, 44(8): 741-763. https://doi.org/10.1007/s12272-021-01348-0 Heller D., Friedrich A., and Killelea B., 2021, Genetic testing for breast cancer patients: is everyone who needs a test getting a test?, Annals of Surgical Oncology, 28: 18-19. https://doi.org/10.1245/s10434-020-09180-4 Hong R., and Xu B., 2022, Breast cancer: an up‐to‐date review and future perspectives, Cancer Communications, 42(10): 913-936. https://doi.org/10.1002/cac2.12358 Hu C., Hart S., Gnanaolivu R., Huang H., Lee K., Na J., Gao C., Lilyquist J., Yadav S., Boddicker N., Samara R., Klebba J., Ambrosone C., Anton-Culver H., Auer P., Bandera E., Bernstein L., Bertrand K., Burnside E., Carter B., Eliassen H., Gapstur S., Gaudet M., Haiman C., Hodge J., Hunter D., Jacobs E., John E., Kooperberg C., Kurian A., Marchand L., Lindstroem S., Lindstrom T., Ma H., Neuhausen S., Newcomb P., O'Brien K., Olson J., Ong I., Pal T., Palmer J., Patel A., Reid S., Rosenberg L., Sandler D., Scott C., Tamimi R., Taylor J., Trentham-Dietz A., Vachon C., Weinberg C., Yao S., Ziogas A., Weitzel J., Goldgar D., Domchek S., Nathanson K., Kraft P., Polley E., and Couch F., 2021, A population-based study of genes previously implicated in breast cancer, New England Journal of Medicine, 384(5): 440-451. https://doi.org/10.1056/NEJMoa2005936 Hu X., Stern H., Ge L., O'brien C., Haydu L., Honchell C., Haverty P., Peters B., Wu T., Amler L., Chant J., Stokoe D., Lackner M., and Cavet G., 2009, Genetic alterations and oncogenic pathways associated with breast cancer subtypes, Molecular Cancer Research, 7(4): 511-522. https://doi.org/10.1158/1541-7786.MCR-08-0107 Ingvarsson S., 1999, Molecular genetics of breast cancer progression, Seminars in Cancer Biology, 9(4): 277-288. https://doi.org/10.1006/scbi.1999.0124 Jiang Y., Ma D., Suo C., Shi J., Xue M., Hu X., Xiao Y., Yu K., Liu Y., Yu Y., Zheng Y., Li X., Zhang C., Hu P., Zhang J., Hua Q., Zhang J., Hou W., Ren L., Bao D., Li B., Yang J., Yao L., Zuo W., Zhao S., Gong Y., Ren Y., Zhao Y., Yang Y., Niu Z., Cao Z., Stover D., Verschraegen C., Kaklamani V., Daemen A., Benson J., Takabe K., Bai F., Li D., Wang P., Shi L., Huang W., and Shao Z., 2019, Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies, Cancer Cell, 35(3): 428-440. https://doi.org/10.1016/j.ccell.2019.02.001
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==